Randomized, placebo-controlled phase 2 trial of a Lactobacillus crispatus
probiotic given intravaginally for prevention of recurrent urinary tract infection.
Efficacy of combined or single use of Lactobacillus crispatus
LT116 and L.
Antimicrobial activities of Lactobacillus crispatus
ATCC 33820 and Lactobacillus gasseri ATCC 33323.
17,43) Ma L et al investigated the effect of condoms and IUCD on vaginal Lactobacilli colonization and concluded that consistent condom use increases the colonization of Lactobacillus crispatus
in the vagina and may protect against BV.
Lactobacillus iners is present with bacterial vaginosis, and Lactobacillus crispatus
prevails in the vaginal flora of women without BV symptoms.
The first group, CST I, is dominated by Lactobacillus crispatus
, which according to the Dr.
Lactin-V contains a hydrogen-peroxide-producing Lactobacillus crispatus
developed as a probiotic that was determined to be safe and tolerable as a vaginal suppository in a phase 1 trial.
This study involved 100 reproductive-aged women (18 to 40 years) with recurrent urinary tract infections (UTI) and current acute, symptomatic, uncomplicated bladder infections who were randomized to receive either Lactobacillus crispatus
of 10 billion CFUs or placebo suppositories daily for 5 days, then once weekly for 10 weeks.
In a randomized, placebo-controlled trial of a vaginal suppository containing Lactobacillus crispatus
in 100 young women, Dr.
a product containing Lactobacillus crispatus
, or placebo (Clin.
Evaluation of random amplified polymorphic DNA (RAPD)-PCR as a method to differentiate Lactobacillus acidophilus, Lactobacillus crispatus
, Lactobacillus amvlovorus.
These include BufferGel, ACIDFORM gel, Lactobacillus crispatus
suppository and genetically modified strains of Lactobacillus.